A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News

Simply Wall St.04-13 08:26

Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627107955?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-13 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627107955","market":"sg","top_or_hot":-1,"title":"A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News","media":"Simply Wall St.","content":"<div>\n<p>Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-13 08:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen","article_id":"2627107955","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627107955","pubTimestamp":1776039976,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ovarian cancer.\nSee our latest analysis for Zentalis Pharmaceuticals.\nThe azenosertib update has arrived alongside intense trading interest, with a 1 day share price return of 49.55% and a year to date share price return of 382.48%. The 1 year total shareholder return sits at 437.40%, but the 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","ZNTL":"Zentalis Pharmaceuticals, LLC"},"translate_title":"Azenosertib剂量选择新闻后Zentalis Pharmaceuticals(ZNTL)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"ZNTL":1.5},"content_text":"Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ovarian cancer. See our latest analysis for Zentalis Pharmaceuticals. The azenosertib update has arrived alongside intense trading interest, with a 1 day share price return of 49.55% and a year to date share price return of 382.48%. The 1 year total shareholder return sits at 437.40%, but the 3 and 5 year total shareholder returns remain sharply negative, suggesting that recent momentum is strong but follows a long period of weak longer term outcomes. If this kind of clinical news has your attention, it can also be useful to see which other healthcare names are moving, starting with 31 healthcare AI stocks With the shares at US$6.61 and trading very close to the current analyst price target, the stock does not look obviously cheap on headline signals. This raises the question of whether there is still a mispricing here or if the market is already factoring in future growth. AdvertisementPreferred Price to Book Multiple of 2.2x: Is It Justified? On simple valuation checks, Zentalis looks inexpensive, with the shares at $6.61 and trading below several fair value markers, including the SWS DCF model estimate of $21.73. Price to book is a common anchor for early stage biopharma, and here Zentalis screens as good value. The current P/B of 2.2x sits below both the US biotechs industry average of 2.3x and a peer average of 2.4x, implying the market is assigning a slightly lower value to the company’s net assets than to comparable names. Alongside this, the SWS DCF model suggests the shares, at $6.61, are trading well below an estimated future cash flow value of $21.73. That gap indicates the model’s cash flow assumptions imply a much higher value than the market is currently willing to pay, which can sometimes happen with clinical stage companies that are still loss making and have no meaningful revenue. For a business reporting a net loss of $137.06m and less than $1m in revenue, cash flow based models and asset based checks like P/B often matter more than earnings ratios. Investors typically weigh these against clinical progress and funding mix, and Zentalis currently relies entirely on higher risk external borrowing, with no lower risk customer deposit funding. Look into how the SWS DCF model arrives at its fair value. Result: Price to Book of 2.2x (UNDERVALUED) However, there are clear risks here, including ongoing net losses of $137.06m and full reliance on external borrowing to support clinical development. Find out about the key risks to this Zentalis Pharmaceuticals narrative. Another Way to Look at It The SWS DCF model paints a very different picture compared with the P/B check, with an estimated future cash flow value of $21.73 per share versus the current price of $6.61. On that view, Zentalis trades at a large discount. This raises a simple question: is the model too optimistic, or is the market too cautious? Look into how the SWS DCF model arrives at its fair value. ZNTL Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Zentalis Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of strong recent returns and ongoing losses makes the picture far from straightforward, so it is worth checking the details for yourself and forming a clear view using the 1 key reward and 4 important warning signs. Looking for more investment ideas? If Zentalis has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could fit your approach.  Spot potential bargains that combine quality and value by scanning 58 high quality undervalued stocks. Prioritize resilience and sleep better at night by filtering for 72 resilient stocks with low risk scores. Get ahead of the crowd by searching the screener containing 23 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zentalis Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627107955","isCrawlerRequest":true}